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Summary In previous pharmacologic studies, the native fluorescent properties of doxorubicin (DOX) have
been utilised to visualise tissue and cellular drug distribution. Such distribution studies provide valuable
additional information to that obtained by measuring tissue drug concentration alone. An alternative
immunocytochemical method of drug localisation using a rabbit immunoadsorbed antiserum to DOX and
silver-enhanced gold-labelled second antibodies has been used to achieve visualisation of DOX in normal and
malignant tissues from drug-treated animals and patients, and in human tumour cell lines treated in vitro.
Non-specific staining in untreated tissues or in controls stained without primary antibody was minimal.
Widespread dark brown to black specific immunostaining was observed in the normal tissues of drug-treated
animals and in rat sarcoma and in the mouse EMT6 mammary tumour. In human breast tumour biopsy
samples obtained at surgery 1 h following a 25 mg intravenous dose of DOX, considerable variation in drug
distribution was observed which appeared to be related to drug concentration. Both nuclear and membrane
staining was apparent; the latter was especially noticeable in human tumour cells grown in the presence of
DOX at concentrations greater than 0.92 JM. Immunolocalisation using silver enhanced gold-labelled reagents
provides an additional technique to study cell and organ specific differences in drug uptake and distribution.
Doxorubicin (DOX) is a widely used anthracycline antibiotic
which has clinical activity against leukaemias, lymphomas
and various solid tumours. While tumour resistance to
anticancer drugs is obviously an important factor in clinical
effectiveness, an equally important consideration in the treat-
ment of solid tumours, which are often poorly vascularised,
is that of drug access. Studies of anthracycline distribution
within tissues and cell compartments have been carried out
based on the natural fluorescence of these compounds
(Egorin et al., 1980; Danesi et al., 1988; Hindenburg et al.,
1989) and this characteristic provides a means of identifying
treatment regimens or drug analogues which may improve
drug delivery to tumour, of correlating drug distributions
with specific organ toxicities, or of comparing intracellular
distribution of drug in anthracycline-sensitive and -resistant
tumours and cells. Phenotypic variations in the intracellular
localisation of DOX have also been demonstrated by
fluorescence (Aghai & Tokes, 1990).
We have previously demonstrated that the distribution of
the anti-cancer drug VP16-213 in normal and malignant
tissues can be visualised using immunocytochemical methods
employing a specific VP16-213 antiserum and enzyme-
labelled second antibodies (Henneberry et al., 1987). In the
case of DOX, such a technique may offer advantages over
fluorescence detection in that it can be carried out by light
microscopy, and provides greater resolution of tissue mor-
phology. The use of specific antibodies also helps to eliminate
non-specific effects, e.g. background fluorescence, which may
occur in fluorescence detection. However, in initial studies,
the enzyme-label technique proved to be insufficiently sen-
sitive to enable the visualisation of DOX in the tissues and
cells examined at the doses used.
An important advance in the field of immunocytochemistry
has been the development of immunogold-labelled antibodies
(Faulk & Taylor, 1971) which, in conjunction with silver
enhancement techniques (Holgate et al., 1983; Springall et al.,
1984), have been shown to have high sensitivity, demons-
trating antigens undetectable by standard enzyme methods.
In addition, the use ofimmunogold probes obviates the need
to use potentially carcinogenic enzyme substrates such as
diaminobenzidine (DAB). This paper describes the applica-
tion of gold silver-enhanced immunocytochemistry to the
visualisation of DOX in selected human and animal tissues,
and in a human tumour cell line grown in vitro.
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Materials and methods
Primary antiserum
The polyclonal DOX antiserum was raised in a rabbit (GR
52) against DOX conjugated to bovine serum albumin (BSA)
(Piall et al., 1982). The antiserum was immunoadsorbed on a
high-capacity aldehyde activated silica (100 nm diameter;
IOOA pore size; Clifmar Associates, Guildford) column, to
which was coupled 100 mg BSA g-' silica beads. Before app-
lication of the crude antiserum (1 ml), the column
(0.7 x 7 cm) was washed with 10ml 0.1 M glycine/HCI pH2,
followed by 20 ml 0.2 M phosphate buffered saline pH 7.4.
After elution of the purified antiserum with 5 ml of the
buffer, the column was washed with glycine/HCI followed by
0.2 M phosphate buffered saline containing 0.1% thiomersal.
The sealed column was then stored at 4'C until required
again.
For immunocytochemistry, the purified antiserum was
diluted 1 in 100 in 0.01 M phosphate buffered saline (PBS)
containing 0.1% BSA, 0.5% sodium azide, pH 7.2.
Tissues and controls
Tissues (liver, kidney, heart, small intestine, sarcoma) were
obtained at the end of infusion from rats treated with 10 mg
DOX kg-', infused intravenously over 1-2 h. EMT6 mam-
mary tumours were obtained from mice 1 h after administra-
tion of 10mg DOXkg' i.p. Human primary breast tumour
biopsy material was obtained from patients during surgery
1 h following the administration of DOX (25 mg i.v.) as
previously described (Stallard et al., 1990). Controls were
either tissues from untreated animals or sections from drug-
treated subjects, which were incubated without specific
antibody.
Cytological samples
A metastatic human breast cancer cell line, ZR75, was grown
in RPMI-1640 medium (Northumbria Biologicals Ltd) until
the cells were almost confluent and then treated with DOX
(0-1,000 ngml-' (0-1.84pM)) at 37°C for 24 h. The IC50
for these cells treated under similar conditions was 36 nM
DOX. The DOX-containing medium was replaced by drug-
free medium and the cells were incubated for a further 24 h
at 37°C. The cells were detached from the flask walls by
trypsinisation, suspended in fresh medium and centrifuged at
1,000 r.p.m. for 5 min. The cells were then resuspended and
Nw.117"Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 65, 82-86IMMUNOGOLD VISUALISATION OF DOXORUBICIN 83
washed twice in 1% sodium citrate (1.5 ml). Ten-fifteen tl
aliquots of the cell suspension were pipetted onto poly-L-
lysine (Sigma) or glycerin-albumen (Raymond A Lamb,
London) coated microscope slides. The slides were allowed to
dry in air, fixed and then immunocytochemically stained as
described below.
Immunocytochemistry
Samples of animal and human tissues were fixed in 10%
neutral buffered formalin and embedded in paraffin wax
using standard histological techniques. Five ym sections were
transferred onto poly-L-lysine coated microscope slides.
For cytological slides, fixation was achieved by three cycles
of alternate freezing (the slides being placed, section upwards
on a metal plate cooled by solid carbon dioxide, for 10 s) and
thawing (2-3 min). Slides were then rinsed 2 x 5 min in PBS.
Fixation was also attempted using formaldehyde/0.1 M PBS
pH 7 (10 ml:500 ml) or acid-alcohol (glacial acetic acid/100%
ethanol, 90 ml:210 ml) for 15 min, followed by 50% ethanol
for 1 min and tap water for 10min, and finally rinsing in
PBS (2 x 5 min).
In order to improve the intensity of DOX immunostaining
over that achieved with immunoperoxidase, sections and
slides were stained using the IntenSE M silver-enhanced
Immunogold staining (IGSS) reagents (Janssen Life Sciences
Products, now available from Amersham International plc).
Briefly, sections were washed with PBS (paraffin sections
being first taken to water) and incubated at room tempera-
ture with 5% normal goat serum (Guildhay Antisera Ltd),
100-200 Ill/slide for 30 mmn followed by incubation overnight
at 4°C in a humidity chamber with specific rabbit anti-DOX
serum (G/R/52) (1 in 100 dilution (100-200p1/slide)). After
incubation with gold-labelled second antibody goat anti-
rabbit IgG AuroProbe (Janssen Life Sciences) (1 in 40 dilu-
tion, 100-200j.l/slide), for 60 min at room temperature in a
humidity chamber, silver enhancement reagent (Janssen Life
Sciences; 4 drops/slide) was added for approximately 15 min
at room temperature. After rinsing in distilled water, the
slides were counterstained in eosin and mounted in DPX.
Full details of the IGSS staining method are given in the
booklet supplied with each IntenSE M kit.
The intensity and distribution of the immunostaining on
tissue sections were assessed using light microscopy. For
ZR75 cytological samples, the percentage of cells stained and
the intensity of staining were scored on an arbitrary scale
(1 = no staining, 10 = most intense staining) and the product
of the two scores was correlated to the dose of DOX
administered and also to intracellular drug concentration
assayed in cell homogenates by radioimmunoassay (RIA)
using the same DOX antiserum (Piall et al., 1982).
Results
Antiserum
Initial staining of rat tissues using unpurified primary anti-
serum G/R/52, resulted in excessive background staining of
control tissue from untreated animals. This non-specific
staining was largely eliminated by purification of the anti-
serum on an immunoadsorbent column containing BSA, the
protein used to prepare the immunising conjugate. Using
ELISA methodology, approximately 84% of non-specific
binding of G/R/52 to BSA-coated microtitre plates was elim-
inated by purification.
Normal animal tissues
In rat tissues obtained at the end of a 1-2 h i.v. infusion of
DOX, widespread specific black staining was seen in the
nuclei and cytoplasm of all tissues except the small intestine
(Figure 1), the nuclear staining corresponding to that seen by
fluorescence microscopy. There was little or no evidence of
non-specific staining in the corresponding tissues from un-
treated control animals. The immunostaining in tissues from
drug-treated animals was distributed throughout the tissues
examined and appeared to be particularly intense in kidney
tubules. The distribution of DOX in cardiac tissue was wide-
spread, and appeared to be similar to that demonstrated in
adjacent sections by native fluorescence and previously
shown by Danesi et al. (1988).
Tumour tissues
In rat sarcoma (not shown) and drug-sensitive mouse EMT6
breast tumour sections, specific staining was widespread but
al
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Figure 1 Distribution of DOX immunogold staining in rat tis-
sues obtained at the end of a 1-2 h i.v. infusion of DOX
(10mg kg-1). a, kidney x 100; b, liver x 400 and c heart x 400.
The staining in tissues from untreated animals is shown in each
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mainly nuclear (Figure 2). In order to demonstrate that this
technique was applicable to clinically-derived samples, sec-
tions of tissue from 20 patients undergoing surgery for breast
cancer were studied in two batches. The staining was distri-
buted throughout the cytoplasm and nuclei although appar-
ently confined mainly to tumour cells (Figure 3). No
immunostaining was seen on sections incubated without
primary antiserum.
There were differences in intensity of staining between the
two batches of slides studied, and the results of all 20 sam-
ples-could not be directly compared. This may be due to the
fact that different batches of both immunoadsorbed specific
antiserum and commercially available reagents were used.
However, it was apparent that within batches there were
marked differences between tumours in the intensity and
distribution of immunostaining which probably reflect the
5-7 fold variation in measured tissue drug concentrations
described previously (Stallard et al., 1990). In the four
samples studied in one batch, tissue drug levels were 479 (no
staining), 1023 (Figure 3a), 650 (Figure 3b) and less than
200 ng g' (Figure 3c). Very intense staining was seen in
large areas of this latter section. The amount ofdrug extract-
ed and measured in the tumour was the lowest in the study
although the plasma concentration was one of the highest
(Stallard, S., personal communication).
Human breast carcinoma cell line: ZR75
There was no evidence of positive immunostaining on drug-
treated ZR75 cell smears fixed either in formaldehyde or in
acid/alcohol. However, on drug-treated cells fixed by freeze/
thaw permeabilisation there was evidence of positive immu-
nostaining especially at doses of DOX about 500 ng ml-'
(0.92pM) in the medium (Figure 4). Subjective immunostain-
ing scores were related to both the dose of DOX administer-
ed, and to the intracellular drug concentration measured by
RIA (Table I).
Discussion
The results show that IGSS, using a drug-specific antiserum,
provides a sensitive, alternative technique for demonstrating
DOX distribution in tissues and in cell culture smears. In
contrast to the very pale staining obtained using an enzyme
label, the IGSS method provided a strong black signal within
minimal background staining following various doses of
DOX including therapeutic doses in patients. Increased sen-
sitivity with immunogold reagents have been described
before. Hacker et al. (1985) were able to obtain staining of a
variety of antigens with IGSS which were not apparent with
the peroxidase-antiperoxidase method (Sternberger et al.,
1970). This difference may be due to a loss of antigenicity
during fixation or processing, leaving sufficient antigen to be
detected only by IGSS.
With respect to solid tumours, chemotherapeutic effective-
ness will inevitably depend upon drug distribution which may
be expected to reflect the pattern of vasculature which in
tumours generally tends to be more extensive at the periphery
than within the tumour (Kerr & Kaye, 1987). Weiss et al.
(1986) attempted to demonstrate this by 3-dimensional recon-
struction of DOX concentrations in mouse colon tumours.
The tumours were dissected into spatially co-ordinated 2 mm
blocks and, after homogenisation, the DOX concentration in
each block was assayed by fluorescence analysis. Concentra-
tions of DOX between and within tumours were found to be
a
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Figure 2 Distribution of DOX immunogold staining in mouse following 25 mg i.v. DOX. a, sample 7,207 x 100, b, sample
EMT6 parent mammary tumour ( x 100) I h following 10mg 7,025 x 400 and c, sample 9,331 x 400. Insets for b and c show
kg-' DOX i.p. Inset shows tumour from untreated animals. controls prepared without primary antiserum.IMMUNOGOLD VISUALISATION OF DOXORUBICIN 85
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Figure 4 Immunogold localisation of DOX in ZR75 human
breast carcinoma cell line (x 400). a, following 1,000 ng ml-'
(1.84 gM DOX in culture medium for 24 h and b, no drug
treatment.
Table I Subjective scores of DOX immunogold staining in ZR75
breast carcinoma cells
Concentration
Dose (ngiLg' % stained Intensity (b) Score
(ngml-') protein) (a) 0-10 (a) x (b)
0 ND 0 0 0
5 ND 29 3.5 101.5
50 13 79 6.4 505.6
500 130 88 8.0 704.0
1,000 721 100 9.7 970.0
Control
50 (no DOX - 0 0 0
antibody)
Thepercentnumber ofcells stained and the intensity ofstaining (on a
scale 1-10)weredeterminedbytwoobserversandthemeanoffivefields
on each slide recorded. Concentration of DOX in the cells was
determined in duplicate by RIA.
widely heterogeneous with lowest levels being found at the
tumour periphery as well as at internal locations. Immuno-
cytochemistry provides a more generally applicable and use-
ful technique for demonstrating such distributions in adjacent
areas of tumour.
As expected, in the human tumour biopsies studied here,
variations in the distribution and intensity ofimmunostaining
were observed from sample to sample. In some tumours the
drug was widely distributed, but in others more discrete areas
of tissue were stained. In general, immunostaining was assoc-
iated with malignant rather than normal tissue, reflecting the
tumour: normal tissue concentration ratio in these patients
which ranged from 1.27 to 8.30 (Stallard et al., 1990). Also,
our results, especially those from in vitro studies, suggest that
the extent ofimmunostaining is related to tissue drug concen-
tration. However, one of the most intensely stained breast
tumour tissues (Figure 3c) had a very low measured drug
concentration which was thought to be due to a low drug
extraction efficiency. Intensely stained areas in tissues may
therefore represent regions when the drug is particularly
tightly bound to cellular components.
The extent to which drug is washed away during the
various sample processing stages has not been studied but it
is evident that a substantial amount of DOX is sufficiently
tightly bound to tissue components to withstand the washing
procedures. Indeed, it is likely that the drug has been 'fixed'
at its binding sites by the neutral buffered formalin. In earlier
studies with VP-16 (Etoposide) immunostaining in frozen
sections was comparable to that in paraffin embedded sec-
tions (Henneberry et al., 1987) indicating that significant
quantitites of drug were not lost during the embedding and
de-waxing procedures. For the in vitro experiment described
here, a second incubation in drug-free medium and several
washing steps were included to ensure that any 'non-speci-
fically bound' drug was eliminated prior to staining.
The precise mode of action(s) of DOX is unknown but it is
thought to include binding to membrane sites (Tritton &
Yee, 1982), accumulation in the cell nucleus and DNA inter-
calation (Dimarco, 1975), the production of reactive oxygen
species (Bachur et al., 1982) and interaction with topoiso-
merase II (Glisson & Ross, 1987). In the results described
here nuclear accumulation was especially evident in the rat
liver sections and the mouse EMT6 tumours while membrane
binding could be seen in stained smears of the parent ZR75
cells treated with higher doses DOX. In preliminary experi-
ments, the intensity of staining in multi-drug resistant MCF7
breast carcinoma cells was much less than in parent cells
even when a 10 fold higher concentration ofdrug was used in
the culture medium. These results reflect the fact that tumour
resistance to anthracyclines is associated with membrane pro-
tein changes including increased synthesis of P-glycoprotein
and increased drug efflux (Lemontt et al., 1988).
Apart from the development of resistance to the drug, the
main limitation of DOX treatment is its cardiotoxicity which
is related to the particular ability of the drug to bind to the
phospholipid cardiolipin. Widespread accumulation of DOX
in rat heart has been demonstrated in this study and pre-
viously by fluorescence (Danesi et al., 1988). Earlier studies
have shown that DOX concentrations are greater in the
kidney than in the heart until 5 h following administration
(Shinozawa et al., 1980). The high degree of immunostaining
seen in the heart sections compared to kidney (Figure 1c)
may represent drug which is tightly bound to a cardio-
specific tissue or cell component. New, putatively less cardio-
toxic analogues of DOX, e.g. epirubicin (Cersosimo & Hong,
1986) are currently being evaluated clinically. The relatively
high cross-reactivity of the G/R/52 and similar antisera with
this analogue could be utilised in the IGSS technique describ-
ed above, to compare the distribution and tissue effects of
these analogues in relation to cardiotoxicity with those of
DOX itself.
The purpose of the present study was to demonstrate that
the tissue distribution of anthracyclines could be visualised
using immunocytochemical methods. The improved sensiti-
vity of the IGSS method over the more coventional enzyme
immunocytochemical techniques has enabled the localisation
of DOX distribution in tissues and cells. The technique has
an important role to play in pharmacological studies of
DOX. Apart from enhanced sensitivity with low background
staining, the IGSS technique offers some other advantages
over more conventional immunocytochemical methods and
fluorescence visualisation. There is potential for use in double
or triple labelling systems, e.g. to co-demonstrate the distri-
bution of P-glycoprotein (Salmon et al., 1989) and the use of
computerised image analysis may be able to provide a more
objective evaluation of drug distribution. More recently, very
small (1 nm diameter) immunogold probes have been produc-
ed which provide a universal reagent for use in light and
electron microscope applications - the latter suggesting the
potential for quantitation of tissue drug levels by IGSS
immunocytochemistry, as well as more detailed information
on intracellular drug distributions and effects.
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